Category Archives: Diabetes

Chapters

00:00 - Intro

00:40 - Abbott OTC CGM

06:20 - Diabetes Technology Pipeline

10:45 - JDRF Rebrands as Breakthrough T1D

15:15 -US FDA Clearance of CamAPS FX

In this episode ofDiabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives,hostsDiana Isaacs, PharmD, and Natalie Bellini, DNP, provide a June 2024 update focusing on a trio of topics across the spectrum of diabetes management. In the episode, hosts discuss the US Food and Drug Administration (FDA) clearance of 2 new over-the-counter (OTC) continuous glucose monitoring (CGM) systems from Abbott, the renaming of JDRF to Breakthrough T1D, and the FDA clearance of the CamAPS FX for people with type 1 diabetes.

After spotlighting Dexcoms Stelo in a previous episode, hosts started off this episode by discussing Abbotts announcement of US Food and Drug Administration clearance for a pair of new OTC CGM devices: the Lingo and the Libre Rio.1

Billed by Abbott as a consumer biowearable, the Lingo is designed for use by consumers 18 years and older looking to improve their overall health by offering them the ability to track glucose and provide personalized insights as well as customized coaching. The Lingo will feature a biosensor designed to be worn on the upper arm with a 14-day wear period. Data obtained by the sensor will be continuously streamed to a smartphone application for the user.1

Unlike the Lingo, the Libre Rio is billed by Abbott as the companys first OTC system for those with type 2 diabetes who do not use insulin and manage their diabetes with lifestyle modifications. The system boasts a measurement range of 40 to 400 mg/dL.1

On June 04, 2024, the JDRF announced it would be changing its name and will now be called Breakthrough T1D. Announced in a simulcast during the organizations annual Government Day Conference, the new name is a reflection of the medical communitys recognition that type 1 diabetes can develop at any age, regardless of family history.2

As an adult and scientist living with type 1 diabetes, I believe our new name, Breakthrough T1D, will help to deepen engagement and support across the entire community as we drive toward curing type 1 diabetes, said Aaron J. Kowalski, PhD, chief executive officer of Breakthrough T1D.2

To complete the episode, the hosts celebrate a long-awaited announcement for those up to date on developments in diabetes technology: the US FDA approval of CamAPS FX.3,4

A prescription-only mobile application developed by CamDiab Ltd, CamAPS FX is designed for use with compatible devices for automated insulin dosing to help manage type 1 diabetes in people 2 years of age or older. However, much of the excitement surrounding the algorithm revolves around it being the first of its kind for use in pregnant patients who may have complications with type 1 diabetes.3,4

Compatible with other interoperable devices that meet pre-specified acceptance criteria, the application works with an integrated continuous glucose monitor to control a compatible insulin pump. At the time of clearance by the US FDA, the CamAPS FX closed-loop algorithm had already received clearance for a similar indication in Europe and been used by more than 27,000 people in 15 countries.3,4

References:

More:
Diabetes Dialogue: June 2024 Updates in Diabetes Tech and Type 1 Diabetes - MD Magazine

ORLANDO, Fla., June 22, 2024 /PRNewswire/ -- Today, the American Diabetes Association (ADA) announced the winners of its Innovation Challenge competition. Innovators showcased novel ideas for diabetes care before a panel of potentialfunders and an audience of professionals in the field, with the goal of furthering transformative solutions for people living with diabetes, their families, and caregivers. Five finalists pitched ideas from the main stage at the ADA's 84th Scientific Sessions and three winners were chosen Diatech Diabetes, Spotlight Communications, and Symbio Cell Tech.

The competition comes amidst a diabetes epidemic affecting over 38 million Americans. Increased efforts to bend the curve of diabetes, coupled with advancements in technology and scientific understanding have created a growing market for diabetes startups.

"The potentially game-changing ideas presented by these innovators bring the ADA's vision of a life free of diabetes and all its burdens closer to reality. We're proud to support emerging advancements in diabetes research and care," said Robert Gabbay, chief scientific and medical officer of the ADA. "Our congratulations to the winners, with appreciation for their hard work and excitement for what's to come."

This year's winners and finalists included:

Winner: Diatech Diabetes A software platform to improve infusion failure detection in insulin pump and automated insulin deliver (AID) systems. The mobile app integrates with insulin pumps allowing people with diabetes to monitor their infusions and avoid hyperglycemia.

Winner: Spotlight Communications A clinical tool to address patient-identified priority concerns and immediately map resources to meet unmet physical, mental and social wellbeing needs.

Winner: Symbio Cell Tech A biotherapy for patients with type 1 diabetes that does not require encapsulation devices or antirejection drugs.

Finalist: Spect A smartphone-enabled telemedicine platform for eye screening that trains medical assistants and returns a diagnostic report in minutes.

Finalist: Valendo Health Delivery of a program to address the shortage of endocrinologists, beginning with increasing clinical capacity and enhancing patient care by delivering telehealth and remote patient monitoring services.

The application period for next year's Innovation Challenge will open in January 2025.

About the American Diabetes Association's Scientific SessionsThe ADA's 84th Scientific Sessions, the world's largest scientific meeting focused on diabetes research, prevention, and care, will be held in Orlando, FL on June 21-24. More than 11,000 leading physicians, scientists, and health care professionals from around the world are expected to convene both in person and virtually to unveil cutting-edge research, treatment recommendations, and advances toward a cure for diabetes. Attendees will receive exclusive access to thousands of original research presentations and take part in provocative and engaging exchanges with leading diabetes experts. Join the Scientific Sessions conversation on social media using #ADAScientificSessions.

About the American Diabetes AssociationThe American Diabetes Association (ADA) is the nation's leading voluntary health organization fighting to bend the curve on the diabetes epidemic and help people living with diabetes thrive. For 83 years, the ADA has driven discovery and research to treat, manage, and prevent diabetes while working relentlessly for a cure. Through advocacy, program development, and education we aim to improve the quality of life for the 136 million Americans living with diabetes or prediabetes. Diabetes has brought us together. What we do next will make us Connected for Life. To learn more or to get involved, visit us at diabetes.org or call 1-800-DIABETES (1-800-342-2383). Join the fight with us on Facebook (American Diabetes Association), Spanish Facebook (Asociacin Americana de la Diabetes), LinkedIn (American Diabetes Association), Twitter (@AmDiabetesAssn), and Instagram (@AmDiabetesAssn).

Media Contact: Amy Robinson [emailprotected]

SOURCE American Diabetes Association

Continued here:
The American Diabetes Association Names Winners of Diabetes Innovation Challenge - PR Newswire

People with diabetes who are hospitalized often face challenges if they use continuous glucose monitoring. Hospital staff may not be familiar with different CGM devices, or may not know how to use them for insulin dosing. And while CGM use in a hospital setting isn't currently approved by the FDA, new research shows that patients benefit from using their own devices, which could be influential in moving away from finger sticks as the standard.

Researchers from Stanford Health Care developed a hospital-wide plan for CGM use for insulin dosing, in a study in 2022 to 2023. The results showed CGM use was effective for patients, with 87.7% success meeting the accuracy criteria for insulin dosing. About 1,500 CGM readings from 135 patients using their personal CGM were validated using a finger stick test. Study results were presented at the 2024 American Diabetes Association Scientific Sessions in Orlando.

Dr. Susan Seav, an endocrinology fellow at Stanford Medicine, and the other researchers in the study developed a chart that nurses could use for making dosing decisions for the majority of hospital patients they treated, who were using Dexcom and Libre sensors.

"We think that the creation and implementation of an inpatient CGM protocol with real-time device accuracy monitoring is feasible and allows for insulin dosing based on personal CGM data," Seav said. "By sharing our experience and our data, we really hope to establish CGM use as part of the standard of care when appropriate. And we also want to encourage and empower other institutions to adopt similar protocols."

The study also found that a large majority of nurses 80% preferred CGM use to finger sticks. And most nurses found inpatient CGM use effective, easy to use, and efficient.

"The ADA has said people should, if at all possible, be allowed to continue to use their CGM right in the hospital," said Dr. Nicholas Argento, diabetes technology director at Maryland Endocrine and Diabetes, who attended a presentation of the study but was not involved in it. "But hospitals need to have a protocol in order to allow this. In this study, the accuracy was excellent."

More:
CGM Use in Hospitals Helps Patients and Nurses - diaTribe Foundation

Findings Highlight the Impact of Insurance Barriers on Managed Diabetes Care for Diverse Populations Living with Type 1 Diabetes

ORLANDO, Fla., June 21, 2024 /PRNewswire/ -- Results from a new study show the impact and importance of continuous glucose monitoring (CGM) that young individuals with diabetes face today. The findings were presented as a Late-Breaking Poster at the 84th Scientific Sessions of the American Diabetes Association (ADA) in Orlando, FL.

Health disparities is a growing concern that significantly impacts diabetes. In nearly all states, those who identify as Black and Native American are more likely than those who identify as Asian American, Hispanic/Latino, and White to die from complications of diabetes. Over half of Hispanic/Latino adults are predicted to develop type 2 diabetes during their lives.

"People with type 1 diabetes are at a heightened risk for health complications as they age. They all deserve access to care and treatment, no matter their no matter their race, income, ZIP Code, age, education, or gender," said Robert Gabbay, MD, PhD, ADA chief scientific and medical officer. "The findings from the studies presented at this year's Scientific Sessions are encouraging, as we strive to develop innovative, evidence-based solutions to support a diverse population of people living with diabetes and maintain their care."

The use of CGM reduces HbA1c and is recommended by the American Diabetes Association within 12 months of a type 1 diabetes diagnosis. This study examines the impact of insurance, race, and ethnicity on the timing of CGM initiation in children with type 1 diabetes and compares glycemic control between those who start CGM within six months of diagnosis versus later.

Children up to age 21 diagnosed with T1D at UCSF Benioff Children's Hospitals between February 2015 and September 2021 (n = 270) were grouped by CGM initiation time. Insurance, race, and ethnicity were analyzed using one-way ANOVA (Kruskal-Wallis H-test) to determine if samples originated from the same distribution. T-tests and Wilcoxon tests compared early and late CGM initiation. Data normality was assessed with QQ plots and density plots.

Results showed that on average publicly insured children started CGM within six months, while privately insured children started CGM within two months. Similar delays were observed for children from historically marginalized racial or ethnic groups compared to White, non-Latinx children. The average HbA1c was 7.5% for children who started CGM within six months of diagnosis, compared to 8.4% for those who started later. Barriers to CGM initiation contribute to less optimal glycemic control for publicly insured and racially and ethnically minoritized children, increasing the risk of complications. Addressing these disparities could improve early blood sugar control and health outcomes.

"Our results highlight the marked difference in HbA1c in children that receive CGM early on," said Mette K Borbjerg, lead author from the Steno Diabetes Center North Denmark and Division of Pediatric Endocrinology, University of California San Francisco. Dr. Borbjerg's co-authors include Annika Kvist (Steno Diabetes Center North Denmark), Kala Mehta (Department of Epidemiology, University of California San Francisco), Niels Ejskjaer (Steno Diabetes Center North Denmark and Department of Internal Medicine and Endocrinology, Aalborg University Hospital), and senior author Jenise Wong (Division of Pediatric Endocrinology, University of California San Francisco)."Ensuring timely CGM access for all children is essential to reduce complication risks.This highlights the need for practices and policies to address barriers to CGM initiation and healthcare access."

Future research should focus on understanding the specific barriers preventing timely CGM initiation. A follow-up study assessing long-term health care outcomes in children with early vs late CGM initiation could provide evidence to advocate for policy changes.

Research presentation details:

Dr. Borbjerg will present the findings at the following Late- Breaking poster session:

About the ADA's Scientific SessionsThe ADA's 84th Scientific Sessions, the world's largest scientific meeting focused on diabetes research, prevention, and care, will be held in Orlando, FL on June 21-24. More than 11,000 leading physicians, scientists, and health care professionals from around the world are expected to convene both in person and virtually to unveil cutting-edge research, treatment recommendations, and advances toward a cure for diabetes. Attendees will receive exclusive access to thousands of original research presentations and take part in provocative and engaging exchanges with leading diabetes experts. Join the Scientific Sessions conversation on social media using #ADAScientificSessions.

About the American Diabetes AssociationThe American Diabetes Association (ADA) is the nation's leading voluntary health organization fighting to bend the curve on the diabetes epidemic and help people living with diabetes thrive. For 83 years, the ADA has driven discovery and research to treat, manage, and prevent diabetes while working relentlessly for a cure. Through advocacy, program development, and education we aim to improve the quality of life for the over 136 million Americans living with diabetes or prediabetes. Diabetes has brought us together. What we do next will make us Connected for Life. To learn more or to get involved, visit us atdiabetes.orgor call 1-800-DIABETES (1-800-342-2383). Join the fight with us on Facebook (American Diabetes Association), Spanish Facebook (Asociacin Americana de la Diabetes), LinkedIn (American Diabetes Association), Twitter (@AmDiabetesAssn), and Instagram (@AmDiabetesAssn).

CONTACT: Amy Robinson [emailprotected]

SOURCE American Diabetes Association

See the original post:
New Research Indicates the Need for Diabetes Continuous Glucose Monitoring to Address Health Disparities - PR Newswire

Findings Reveal Efficacy of Novel Inhaler to Improve Glycemic Control for Patients with Type 1 Diabetes

ORLANDO, Fla., June 22, 2024 /PRNewswire/ --Today, findings from INHALE-3, a pivotal trial examining the use of inhaled insulin in adults with type 1 diabetes (T1D), were announced, highlighting the potential of an alternative insulin solution to enhance diabetes management. The results were presented as a symposium at the 84th Scientific Sessions of the American Diabetes Association (ADA) in Orlando, FL.

Type 1 diabetes affects 11.6% of the American population and millions of individuals globally, requiring ongoing insulin therapy to manage blood glucose levels. Traditional insulin delivery methods include multiple daily injections or automated insulin delivery systems. However, for some patients, there is a need for new solutions to improve convenience, ease of use, and effective glycemic management.

INHALE-3, a randomized trial, compared the efficacy of an inhaled insulin regimen (Afrezza) plus degludec insulin (Tresiba) against usual care over 17 weeks at 19 centers in the U.S. The trial included 123 adults with type 1 diabetes divided into two groups: one receiving inhaled insulin (Afrezza) plus degludec insulin, and the other continuing their usual care, which included automated insulin delivery systems in about half or multiple daily injections. The study's primary endpoint was a change in HbA1c levels, a critical marker of long-term blood glucose control. Secondary endpoints included changes in time-in-range and hypoglycemia measured with continuous glucose monitoring and patient-reported outcomes on insulin delivery satisfaction.

More participants using the inhaled insulin regimen experienced significant improvements in HbA1c levels compared to those on usual care. Notably, 21% of those on inhaled insulin had an HbA1c improvement of greater than 0.5%, while this was seen in only 5% of those with standard care. Furthermore, among participants who had an HbA1c level greater than or equal to 7% at the start of the study, 21% of those on inhaled insulin achieved the HbA1c goal of less than 7% while no participants receiving standard care achieved this HbA1c goal. Nineteen percent of participants who switched from using an automated insulin delivery system to using inhaled insulin plus degludec achieved an HbA1c improvement greater than 0.5%. In contrast to these positive findings, the study found that the insulin regimen with inhaled insulin and degludec was not for everyone: 26% of the patients in the inhaled insulin group had a worsening of HbA1c greater than 0.5% compared with 3% with standard care. Importantly, over half of the study participants wished to continue the inhaled insulin after the study completion.

"The INHALE-3 study's findings will impact diabetes management by providing healthcare providers and patients with an alternative insulin delivery method," said Irl B. Hirsch, MD, University of Washington, and lead author of the study. "These results will assist in better informing clinical decisions and tailoring treatment plans to individual patient needs, potentially improving adherence, patient satisfaction, and overall outcomes."

Building on the promising results of INHALE-3, further research will focus on the impact of inhaled insulin on a broader patient population, including pediatrics and pregnancy. These studies aim to reinforce the role of inhaled insulin in comprehensive diabetes care.

Research presentation details:

Dr. Hirsch will present the findings at the following symposium:

About the ADA's Scientific Sessions

The ADA's 84th Scientific Sessions, the world's largest scientific meeting focused on diabetes research, prevention, and care, will be held in Orlando, FL on June 21-24. More than 11,000 leading physicians, scientists, and health care professionals from around the world are expected to convene both in person and virtually to unveil cutting-edge research, treatment recommendations, and advances toward a cure for diabetes. Attendees will receive exclusive access to thousands of original research presentations and take part in provocative and engaging exchanges with leading diabetes experts. Join the Scientific Sessions conversation on social media using #ADAScientificSessions.

About the American Diabetes Association

The American Diabetes Association (ADA) is the nation's leading voluntary health organization fighting to bend the curve on the diabetes epidemic and help people living with diabetes thrive. For 83 years, the ADA has driven discovery and research to treat, manage, and prevent diabetes while working relentlessly for a cure. Through advocacy, program development, and education we aim to improve the quality of life for the over 136 million Americans living with diabetes or prediabetes. Diabetes has brought us together. What we do next will make us Connected for Life. To learn more or to get involved, visit us atdiabetes.orgor call 1-800-DIABETES (1-800-342-2383). Join the fight with us on Facebook (American Diabetes Association), Spanish Facebook (Asociacin Americana de la Diabetes), LinkedIn (American Diabetes Association), Twitter (@AmDiabetesAssn), and Instagram (@AmDiabetesAssn).

Contact: Amy Robinson [emailprotected]

SOURCE American Diabetes Association

Read more:
Study Shows Promising Results for Inhaled Insulin as Treatment for Type 1 Diabetes - PR Newswire

An analysis of the SURMOUNT 1 and 2 trials presented at the 84th American Diabetes Association Scientific Sessions offers further insight into the differences in weight loss observed among people with and without type 2 diabetes achieved with use of tirzepatide.

Results of the study, which leveraged propensity score matching and mixed models for repeated measures (MMRM) analysis to compare the effect of Eli Lilly and Companys dual GIP/GLP-1 receptor agonist in those with overweight or obesity based on diabetes status, suggest the differences in weight reductions observed persisted after matching key baseline characteristics, which investigators purport indicates other contributing factors drive these differences.

The current study was led by Rodolfo Galindo, MD, of Emory University, to better understand potential drivers of the difference in effects seen with tirzepatide on body weight reductions in people with overweight or obesity with or without type 2 diabetes. With this in mind, investigators designed their study to use propensity score matched cohorts, with matching based on age, gender, weight, BMI, antidepressant use or depression, and obesity-related comorbidities, in MMRM analysis to compare the percent of weight reduction achieved at week 72 between those with and without type 2 diabetes form within SURMOUNT-1 and SURMOUNT-2.

Investigators pointed out initial analysis of the cohorts revealed those in SURMOUNT-2 were older, had a greater proportion of more males, lower weight, greater HbA1c, and greater comorbidity burden compared to their counterparts in SURMOUNT-1.

Results of the ADA 2024 study indicate the differences in weight reduction observed at week 72 remained even after propensity score matching, with those in the SURMOUNT-1 cohort achieving greater levels of body weight reduction than their counterparts in SURMOUNT-2 with type 2 diabetes.

For more on the study, check out our interview with study investigator W. Timothy Garvey, MD, director of the Diabetes Research Center at the University of Alabama - Birmingham.

Relevant disclosures for Dr. Garvey include Boehringer-Ingelheim, Novo Nordisk, Eli Lilly and Company, Merck & Co., Inc., Alnylam Pharmaceuticals, Inc., Fractyl Health, Inc., Inogen, Epitomee, Pfizer Inc., and Neurovalens.

References:

See the original post:
Timothy Garvey, MD: Drivers of Differences in Weight Loss with Incretins Based on Diabetes Status - MD Magazine

Tony Thompson thought he was taking a type of insulin when he was prescribed Ozempic to treat his diabetes in 2021.

The Zephyrhills resident gave himself the medication through weekly injections. After a few weeks, he found himself barely eating and favorite meals like hamburgers and fries began to smell awful to him. He quickly shed 17 pounds.

Soon after that, Thompson, 60, began to suffer severe stomach pains. His condition deteriorated even more on a trip to Georgia when he reached a fourth day without a bowel movement. The pain was so bad, he said, friends had to drive him home as he couldnt risk taking his return flight.

He also blames the drug for later developing pancreatitis, which required surgery to remove his gallbladder.

I felt like I was a chemo patient, he said. I couldnt stand the smell of food.

Thompson and other Tampa Bay residents are among thousands who have joined a mass legal action against Novo Nordisk, the manufacturer of Ozempic and Wegovy, a similar drug used for obesity. The lawsuit claims that the company failed to warn patients that Ozempic, hailed as a miracle drug for those battling diabetes and obesity, causes gastroparesis, also known as stomach paralysis.

Both Wegovy and Ozempic work by tricking the body into feeling that its full. Thats achieved through an ingredient known as a semaglutide, which mimics the GLP-1 hormone produced by the body when eating. They also slow the progress of food through the digestive system.

In September, the Food and Drug Administration updated Ozempics labeling to add ileus, a temporary condition when the intestines stop working properly and cant push food and waste out of the body, as a reported adverse reaction to the drug. There is no warning about gastroparesis.

Three recent preliminary studies found that patients using GLP-1 drugs are at a higher risk for gastroparesis, according to a CNN report.

GLP-1 drugs have soared in popularity in recent years with Medicare paying out $5.7 billion in 2022 for three popular brands, according to research by KFF. About one in eight Americans have taken GLP-1 type drugs, according to a KFF survey.

Those patients were put at risk by Novo Nordisk, which should have known about the risks to the gastrointestinal system, said Andrew Van Arsdale, a managing partner of AVA Law Group, which is representing about two thousand users of the medications.

There are some very dangerous side effects and these manufacturers have an obligation to put patients, consumers, doctors in the best position they can to make that risk benefit analysis to take that product, he said. Thats all were asking here.

Subscribe to our free DayStarter newsletter

Well deliver the latest news and information you need to know every morning.

Want more of our free, weekly newslettersinyourinbox? Letsgetstarted.

With 18 lawsuits filed in 11 court districts, the legal challenge is proceeding through a single test case filed on behalf of a Michigan women, who the lawsuit states she was hospitalized on Jan. 4 for extreme pain, vomiting and stomach paralysis that required an endoscopic procedure. She also was given painkillers for an inflamed esophagus.

Novo Nordisk disputes the allegations in the lawsuits and said in a company statement provided to the Tampa Bay Times that it plans to contest the cases. GLP-1 medicines have been used to treat type 2 diabetes for more than 18 years, and for the treatment of obesity for 8 years, it states.

Novo Nordisk stands behind the safety and efficacy of all of our GLP-1 medicines when they are used as indicated and when they are taken under the care of a licensed healthcare professional, the statement reads.

Go here to read the rest:
Tampa Bay residents among those alleging Ozempic caused stomach paralysis - Tampa Bay Times

This study was conducted using medical record data from four centers in three provinces and cities of China and has thus pioneered the construction of a clinical prediction model for NODAP and implemented risk stratification. This study represents the first attempt to establish a nomogram and an online web-based risk calculator for predicting the risk of NODAP. At a median follow-up of 4.6 years (IQR, 2.38.6 years), the incidence of NODAP was established at 46.52%. The risk of NODAP can be appropriately evaluated through FPG level, LDL-C level, hypertension, family history of diabetes and use of diuretics. Our study is the first to report the long-term NODAP incidence rate in Chinese patients with ACS post-PCI, suggesting a high risk of new-onset diabetes that necessitates widespread attention. The prediction model we developed underwent internal and external validation with results, indicating good predictability.

Our predictive model revealed that the long-term incidence of NODAP exceeds the reported incidence of type 2 diabetes in the Chinese population15. Having a history of ACS might serve as an independent risk factor for new-onset diabetes, aligning with results drawn from other cohort study16. Nearly half of patients who undergo PCI must manage diabetes-related medical burden, thus underscoring the importance of appropriate and timely prediction of NODAP. Currently, there are more than 30 prediction models for the incidence of diabetes, each based on different populations17, with some models predicting the risk of new-onset diabetes in patients with coronary heart disease8. However, only one previous study has focused on the risk factors and incidence of NODAP in the Asian population6, with a lack of NODAP prediction models. Our study used rigorous methodology to tackle challenges such as missing data, model building, and internal and external validation, providing a clearer understanding of the groups at high-risk of NODAP.

Glycolipid metabolism levels were identified as significant risk factors for predicting the risk of NODAP, a conclusion that aligns with the findings of several prior studies that developed models to predict new diabetes onset8,18,19. Chun et al. determined through univariate and multivariate regression analyses that the risk factors for NODAP include FPG level100mg/dL, TG level150mg/dL, high body mass index (BMI), and high-intensity statins and that FPG is more influential than other factors6. FPG levels are significantly associated with the risk of diabetes20, and each 1 mg/dL increase in FPG leads to a 9% increase in the risk of diabetes, not only in patients with impaired fasting glucose, but also even in patients with normal FPG levels (9099mg/dL)21. 2 h postprandial glucose (2hPG) is also an indicator for detecting blood glucose levels, but studies have shown that the inclusion of 2hPG and insulin resistance in the prediction model did not significantly improve the predictive accuracy of the model22,23, and therefore NODAP risk prediction by incorporating a convenient and economical FPG is reliable and practical.

There is a consensus that higher LDL-C levels lead to an increased risk of cardiovascular events24,25, and LDL-C levels are the primary therapeutic target for lipid-lowering therapy in patients with coronary artery disease. Meanwhile, LDL-C has also been found to be associated with an increased risk of diabetes26,27, and the mechanism may be related to abnormal cholesterol metabolism affecting pancreatic -cell membrane function and pancreatic cholesterol deposition, which leads to pancreatic -cell dysfunction affecting glucose metabolism28,29,30. The prediction model in this study showed that LDL-C was also a very strong predictor of NODAP, and LDL-C levels were also significantly associated with the onset of NODAP, so controlling LDL-C levels in patients has the additional benefit of preventing and controlling the development of NODAP in addition to the reduced cardiovascular benefit31, but the specific mechanism of the effect of LDL-C on NODAP has yet to be investigated.

Family history of diabetes is a well-known risk factor for type 2 diabetes32, and the same results were obtained in this study for NODAP. Family history increases the risk of diabetes mellitus, which is thought to be mediated by a combination of genetic, environmental, and lifestyle pathways. Genetic susceptibility to diabetes mellitus has been demonstrated by several genome-wide association studies (GWAS), which have linked susceptibility location to pancreatic -cell dysfunction, insulin resistance, and other factors33.

In addition, this study showed that NODAP risk was strongly associated with a history of hypertension rather than with transient values of BP. Hypertension and diabetes mellitus share multiple metabolic syndrome phenotypes including higher body mass index. abdominal obesity, hyperinsulinemia and hypertriglyceridemia34,35, and pathological processes such as dysregulation of reninangiotensinaldosterone system (RAAS), insulin resistance, and inflammation in hypertension can contribute to diabetes mellitus36,37. Therefore, our findings suggest that closer attention should be paid to glycemic indicators in patients undergoing PCI with hypertension.

Although a history of hypertension and a family history of diabetes are non-modifiable factors, evidence from several randomized controlled trials has demonstrated that the onset of diabetes can also be effectively delayed by improving lifestyle38,39. Therefore, our findings suggest that closer attention should be paid to the glycemic indexes of patients undergoing PCI with a family history of hypertension and diabetes, and consideration should be given to reducing the risk of NODAP through stricter lifestyle control.

Patients undergoing PCI are more likely to have hypertension and poor cardiac function and have more complex medications. Therefore, in our study we also considered the influence of prescribed medications, including antihypertensive drugs, psychotropic drugs, diuretics, and various types and intensities of statins on NODAP. We ultimately identified significant correlations between diuretics and NODAP, aligning with the outcomes of several clinical studies40,41. The mechanism by which diuretics affect glucose metabolism is mostly thought to be an indirect effect on insulin secretion due to diuretic-induced hypokalemia42, but its benefits in terms of reducing the occurrence of cardiovascular events are much greater43, and therefore it is still possible to use this drug for treatment with a combination of potassium-preserving diuretics or increased potassium supplementation and thus improvement of glucose metabolism, although the exact mechanism has not yet been fully elucidated44. This suggests that in patients at high risk of NODAP who require diuretic therapy, combined potassium-preserving measures may be considered to reduce the risk of morbidity. Previously, diuretics have also been found to have a dose-related effect on diabetes, and small doses of diuretics may not increase insulin resistance or insulin release45,46. We have not conducted further studies on the dose to be explored in the future. While previous studies on patients post-PCI have indicated that statin treatment increases the risk of NODAP by 27%11, and high-intensity statin treatment increases the risk of NODAP by 48%6, our study did not establish any association between statins or high-intensity statins and an increased risk of NODAP. Considering that the cardiovascular benefits of statin drugs considerably outweigh the adverse effects of new-onset diabetes47,48, statin drugs remain the primary choice for patients post-PCI.

In this study, we revealed that NODAP is a consequence of the combined effects of factors such as genetics, metabolism, and medication. We classified the risk of NODAP into low (11.339.7%), moderate (39.852.8%), and high (52.990.0%) risk. This stratification allows for improved formulation of post-PCI lifestyle and preventive antidiabetic regimens. Specifically, in the clinic, we can provide active NODAP preventive treatment to patients in advance based on their risk prediction results combined with diabetes prevention and treatment guidelines49. For example, if a patient is screened as intermediate risk, it is recommended that he/she should first control modifiable NODAP risk factors, including improving lifestyle, controlling glucose and lipid levels, etc. If he/she is screened as high risk, it is recommended that he/she should carry out intensive lifestyle interventions, including dietary control, exercise and avoiding the use of diuretics as much as possible. This study provides a precise risk calculator for patients with NODAP as well as prompts healthcare workers, especially those in the cardiovascular field, to pay attention to new-onset diabetes and underscores the urgent need for proactive NODAP prevention.

Despite its strengths, there are several limitations to this study: first, it relies on data from hospitals across three provinces and cities in China, with data from the chosen regions being both limited and unevenly spread, thus there may be selection bias. The long follow-up duration of the study may introduce potential attrition bias, and the precise onset date of diabetes could not be determined. Second, this research is a database-oriented retrospective study; therefore, there may be reporting inaccuracies or missing variables, such as height, weight and waist circumference reflecting obesity and type of ACS, number of diseased vessels, and number of stents implanted reflecting severity of the condition, as well as the inevitable recollection bias of the case data. And it was also not possible to obtain variable characteristics of lifestyle, dietary patterns, and frequency of exercise that may also affect NODAP. The lack of comprehensiveness of the variables covered also resulted in an inability to effectively compare with previous diabetes prediction models. Third, there are many differences between the training and validation cohort population characteristics, which may be related to the fact that the two parts of the cohort came from different provinces, different hospitals, and different severity of the disease, etc. More research centers, larger sample sizes, and more research variables need to be included to further externally validate the model efficacy. Additionally, the laboratory indicators used for diagnosing new-onset diabetes were dependent on glycated, fasting, and random blood glucose levels, which may not fully represent the long-term blood glucose control. Future research using oral glucose tolerance test results could potentially offer higher diagnostic sensitivity and precision. Lastly, we have only established a NODAP prediction and risk stratification system, and have not studied the prognosis of patients at different risks with different treatment modalities, nor have we been able to determine a causal relationship. Further studies are needed to investigate the effects of different management strategies on the long-term prognosis of patients undergoing PCI and the specific mechanisms linking these factors to NODAP.

Read more here:
Development, validation and visualization of a web-based nomogram for predicting risk of new-onset diabetes after ... - Nature.com

The Republican senator met with the famous musician in Washington D.C. to talk about screenings for Type 1 diabetes.

MAINE, USA Sen. Susan Collins met with famous R&B artist Usher in Washington D.C. to discuss the available screenings for Type 1 diabetes, on Thursday.

Usher told Collins, R-Maine, about his son who has Type 1 diabetes (TD1) and advocated for better access to diabetes screening for families, to increase early detection, according to a press release from Collins' office.

Type 1 diabetes can occur in all ages but is the most common type of diabetes in children, according to the Centers for Disease Control and Prevention.

During their meeting, Collins and Usher discussed the impact screening and early detection can have. They agreed it would allow families time to plan and prepare for a life with the disease and provide opportunities for individuals to participate in clinical trials or other therapies that could help delay clinical onset, the release stated.

Collins recently introduced the Strengthening Collective Resources for Encouraging Education Needed (SCREEN) for Type 1 Diabetes Act with Senator Jeanne Shaheen, D-New Hampshire, to improve early detection, according to the release.

"This bill would direct the CDC to conduct a national public awareness campaign about the signs and symptoms of T1D for both healthcare providers and the public, as well as the benefits of early detection and screening," the release stated.

"Early detection of Type 1 diabetes can prevent life-threatening conditions like diabetic ketoacidosis and potentially allow for the use of therapeutics to delay the clinical onset of the condition, helping to improve patients' quality of life and reliance on insulin," Collins stated. "It was a pleasure to talk about the importance of Type 1 diabetes screening with Usher in Washington and hear about his impressive son. I thanked Usher for lending his voice and platform to increasing awareness of the burden of Type 1 diabetes."

See the original post here:
Senator Collins and Usher talk diabetes screening in Washington - NewsCenterMaine.com WCSH-WLBZ

Leading Diabetes Scientific Sessions Meeting Will Present Groundbreaking Data on Key Topics Including: Obesity, Technology, AI Health and the Latest in Diabetes Innovation

ORLANDO, Fla., June 13, 2024 /PRNewswire/ -- From June 2124, the American Diabetes Association (ADA) will host the 84th Scientific Sessions in Orlando, FL. The ADA's Scientific Sessions is the world's largest diabetes meeting, convening more than 11,000 leading physicians, scientists, researchers and health care professionals from around the globe. The hybrid meeting will feature the latest scientific findings in diabetes, including more than 200 sessions and 2,000 original research presentations at the Orange County Convention Center.

Diabetes is among the top 10 leading causes of death in the United States, with more than 1.4 million new cases diagnosed each year. Over the past 20 years, the number of adults diagnosed with diabetes has more than doubled due to factors like increased obesity, weight gain and aging. During the annual meeting, the ADA is highlighting the latest cutting-edge advances in diabetes research and care.

Among the key themes, you can expect:

"As we commence the 84th Scientific Sessions, we are proud of our program that underscores our commitment to addressing the multifaceted challenges of diabetes," said Robert Gabbay, MD, PhD, the ADA's chief scientific and medical officer. "This year's program reflects our dedication to advancing research, fostering innovation, and ultimately improving the lives of those affected by diabetes. We look forward to an engaging and impactful event that will inspire and drive the future of diabetes care, at a pivotal time of pharmacological and technological advances in the field."

Other notable topics and themes highlighted in the presentations at the 84th Scientific Sessions include eye health, health disparities, diabetes and obesity related cancers, and early risk monitoring. Most sessions, in addition to the 60-plus livestreamed sessions, will be available for on-demand viewing for attendees following the meeting through August 26.

"This year's Scientific Sessions is set to highlight the latest and greatest advances in diabetes research with an exceptional, data-driven program," said Alice Y.Y. Cheng, MD, FRCPC, chair of the 84th Scientific Sessions Planning Committee. "Whether you're joining us in-person or virtually, you'll have the opportunity to engage with leading experts, participate in dynamic discussions, and gain valuable insights that will drive the future of diabetes care."

Learn more about the 84th Scientific Sessions.For access to program navigation, educational session information, news updates, abstracts, and exhibitor information, the 2024 ADA Scientific Sessions mobile app and the online planner are your go-to meeting resources.

For more information, please contact the ADA Scientific Sessions media at [emailprotected].

Embargo Policy:

Oral presentations: Oral presentations are embargoed from the time of submission until the start of their presentation at the 84th Scientific Sessions.

Symposiums (including late-breaking symposiums): Symposiums and presentations within symposiums are embargoed until the beginning of the Symposium session at the 84th Scientific Sessions.

Poster presentations (including late-breaking posters): Poster presentations are embargoed from the time of submission until Friday, June 21, 2024, at 6:30 p.m. ET.

About the American Diabetes Association's Scientific SessionsThe ADA's 84th Scientific Sessions, the world's largest scientific meeting focused on diabetes research, prevention, and care, will be held in Orlando, FL on June 21-24. More than 11,000 leading physicians, scientists, and health care professionals from around the world are expected to convene both in person and virtually to unveil cutting-edge research, treatment recommendations, and advances toward a cure for diabetes. Attendees will receive exclusive access to thousands of original research presentations and take part in provocative and engaging exchanges with leading diabetes experts. Join the Scientific Sessions conversation on social media using #ADAScientificSessions.

About the American Diabetes AssociationThe American Diabetes Association (ADA) is the nation's leading voluntary health organization fighting to bend the curve on the diabetes epidemic and help people living with diabetes thrive. For 83 years, the ADA has driven discovery and research to treat, manage, and prevent diabetes while working relentlessly for a cure. Through advocacy, program development, and education we aim to improve the quality of life for the over 136 million Americans living with diabetes or prediabetes. Diabetes has brought us together. What we do next will make us Connected for Life. To learn more or to get involved, visit us at diabetes.orgor call 1-800-DIABETES (1-800-342-2383). Join the fight with us on Facebook (American Diabetes Association), Spanish Facebook (Asociacin Americana de la Diabetes), LinkedIn (American Diabetes Association), Twitter (@AmDiabetesAssn), and Instagram (@AmDiabetesAssn).

SOURCE American Diabetes Association

More:
The American Diabetes Association Kicks Off the 84th Scientific Sessions with Breakthrough Diabetes Research - PR Newswire